Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: IDEAYA is a precision medicine oncology company focused on discovering and developing transformative therapies for cancer, specifically targeting molecularly defined solid tumors. The company has no approved products and generates revenue solely through collaboration agreements.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $15,417 | $0 |
| Net Loss | $(210,991) | $(149,669) |
| Net Loss Per Share (Basic & Diluted) | $(2.33) | $(1.69) |
| Research & Development Expenses | $204,415 | $145,112 |
| General & Administrative Expenses | $41,837 | $28,083 |
| Cash, Cash Equivalents & Marketable Securities | $1,242,889 | $1,049,685 |
| Accumulated Deficit | $(947,530) | $(772,510) |
Liquidity: As of June 30, 2026, the company held approximately $1.24 billion in cash, cash equivalents, and marketable securities. Management believes these funds are sufficient to finance operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $15.4 million in collaboration revenue for the six months ended June 30, 2026, compared to zero in the prior year period. This revenue stems from the Servier License Agreement executed in August 2025.
- Increased Operating Expenses: Total operating expenses rose 42% year-over-year to $246.3 million. R&D expenses increased by $59.3 million (41%) and G&A expenses increased by $13.8 million (49%), driven by clinical trial advancements, personnel growth, and commercial preparation activities.
- Net Loss Expansion: Net loss increased by $61.3 million (41%) to $211.0 million, primarily due to higher operating costs outpacing collaboration revenue and a decrease in interest income.
- Capital Raising: In June 2026, the company completed a follow-on public offering, raising approximately $345.0 million in gross proceeds ($323.4 million net) through the sale of common stock and pre-funded warrants. Additionally, $33.1 million was raised via an at-the-market offering program.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Darovasertib (PKC Inhibitor): The lead asset for uveal melanoma. In April 2026, the company reported positive topline data from the OptimUM-02 Phase 2/3 trial, meeting its primary endpoint for progression-free survival. An NDA submission is planned for the second half of 2026.
- Pipeline Progress: The company is advancing multiple programs including IDE849 (DLL3 ADC), IDE034 (B7H3/PTK7 ADC), and IDE892 (PRMT5 inhibitor). Clinical data updates for several candidates are targeted for the second half of 2026.
- Financial Outlook: The company expects to continue incurring significant operating losses as it advances clinical development and prepares for potential commercialization. Future funding requirements depend on clinical trial outcomes and regulatory approvals.
Risks and Contingencies
- Capital Requirements: The company has an accumulated deficit of $947.5 million and requires substantial additional capital to fund operations. Failure to secure financing could force delays or termination of development programs.
- Regulatory and Clinical Risks: Success depends on the outcome of clinical trials and regulatory approvals, which are uncertain. Delays or failures in trials could materially impact the business.
- Collaboration Dependencies: Revenue and development progress rely heavily on strategic partners (e.g., Servier, Pfizer, Hengrui, AstraZeneca). Changes in these relationships could affect financial performance.
Key Facts for Investor Verification
- NDA Timeline: Verify the company's ability to submit the New Drug Application (NDA) for darovasertib in the second half of 2026 as planned.
- Cash Burn Rate: Monitor the rate of cash consumption given the $211 million net loss in the first half of 2026 and the $1.24 billion cash balance.
- Servier Revenue Recognition: Confirm the timing and amount of future revenue recognition from the Servier License Agreement, specifically regarding the $147 million in remaining performance obligations.
- Clinical Milestones: Track upcoming data readouts for IDE849, IDE034, and IDE892 scheduled for the second half of 2026, which may trigger milestone payments or influence partnership valuations.
- Dilution Risk: Assess the impact of the recent follow-on offering and at-the-market sales on existing shareholders, noting the issuance of 7.2 million shares and 5.5 million pre-funded warrants in June 2026.